CY1112808T1 - Μειγματα ολιγοσακχαριτων προερχομενων απο την ηπαρινη, η παρασκευη τους και φαρμακευτικες συνθεσεις που τα περιεχουν - Google Patents

Μειγματα ολιγοσακχαριτων προερχομενων απο την ηπαρινη, η παρασκευη τους και φαρμακευτικες συνθεσεις που τα περιεχουν

Info

Publication number
CY1112808T1
CY1112808T1 CY20121100489T CY121100489T CY1112808T1 CY 1112808 T1 CY1112808 T1 CY 1112808T1 CY 20121100489 T CY20121100489 T CY 20121100489T CY 121100489 T CY121100489 T CY 121100489T CY 1112808 T1 CY1112808 T1 CY 1112808T1
Authority
CY
Cyprus
Prior art keywords
activity
hexasaccharide
oligosaccharides
preparation
mixtures
Prior art date
Application number
CY20121100489T
Other languages
Greek (el)
English (en)
Inventor
Vesna Biberovic
Luc Grondard
Pierre Mourier
Christian Viskov
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of CY1112808T1 publication Critical patent/CY1112808T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CY20121100489T 2002-10-10 2012-05-30 Μειγματα ολιγοσακχαριτων προερχομενων απο την ηπαρινη, η παρασκευη τους και φαρμακευτικες συνθεσεις που τα περιεχουν CY1112808T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0212584A FR2845686B1 (fr) 2002-10-10 2002-10-10 Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
EP03807882A EP1556414B1 (fr) 2002-10-10 2003-10-08 Melanges d'oligosaccharides derives d'heparine, leur preparation et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
CY1112808T1 true CY1112808T1 (el) 2016-02-10

Family

ID=32039597

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100489T CY1112808T1 (el) 2002-10-10 2012-05-30 Μειγματα ολιγοσακχαριτων προερχομενων απο την ηπαρινη, η παρασκευη τους και φαρμακευτικες συνθεσεις που τα περιεχουν

Country Status (35)

Country Link
EP (1) EP1556414B1 (enExample)
JP (2) JP5021898B2 (enExample)
CN (6) CN101810637A (enExample)
AT (1) ATE548393T1 (enExample)
AU (1) AU2003300161B2 (enExample)
BR (1) BR0315149A (enExample)
CA (1) CA2501546C (enExample)
CY (1) CY1112808T1 (enExample)
DK (1) DK1556414T3 (enExample)
EC (1) ECSP055722A (enExample)
ES (1) ES2383597T3 (enExample)
FR (1) FR2845686B1 (enExample)
GT (1) GT200300181A (enExample)
HN (1) HN2003000312A (enExample)
IL (1) IL167868A (enExample)
MA (1) MA27398A1 (enExample)
MX (1) MXPA05003321A (enExample)
MY (1) MY142376A (enExample)
NI (1) NI200300087A (enExample)
NO (1) NO20052170L (enExample)
NZ (1) NZ539229A (enExample)
OA (1) OA12940A (enExample)
PA (1) PA8584201A1 (enExample)
PE (1) PE20040507A1 (enExample)
PT (1) PT1556414E (enExample)
RS (1) RS20050274A (enExample)
RU (1) RU2332424C2 (enExample)
SI (1) SI1556414T1 (enExample)
SV (1) SV2004001626A (enExample)
TN (1) TNSN05101A1 (enExample)
TW (1) TWI332010B (enExample)
UA (1) UA81925C2 (enExample)
UY (1) UY28016A1 (enExample)
WO (1) WO2004033503A1 (enExample)
ZA (1) ZA200502787B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2845686B1 (fr) * 2002-10-10 2013-08-30 Aventis Pharma Sa Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
FR2857971B1 (fr) * 2003-07-24 2005-08-26 Aventis Pharma Sa Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
EP2447285A3 (en) * 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2008068854A1 (ja) 2006-12-05 2008-06-12 Glycoscience Laboratories, Inc. 変形性関節症の治療剤
WO2010087207A1 (ja) 2009-02-02 2010-08-05 大塚化学株式会社 低分子量多硫酸化ヒアルロン酸誘導体及びこれを含有する医薬
EP2233145A1 (en) 2009-03-19 2010-09-29 Sanofi-Aventis A dose of AVE5026 for the treatment of venous thromboembolism in patients with severe renal impairment
EP2399591A1 (en) 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
EP2399592A1 (en) 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings and major bleedings
EP2399590A1 (en) 2010-06-25 2011-12-28 Aventis Pharma S.A. Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopaedic surgery
EP2399593A1 (en) 2010-06-28 2011-12-28 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in orthopaedic surgery with improved benefit-risk profile
JP2012046511A (ja) * 2010-07-30 2012-03-08 Otsuka Chem Co Ltd 低分子量多硫酸化ヒアルロン酸誘導体を含有する医薬
DK3144325T3 (da) * 2010-09-14 2021-01-25 Univ Miyazaki Heparin med høj renhed og fremstillingsfremgangsmåde dertil
WO2012055843A1 (en) 2010-10-28 2012-05-03 Aventis Pharma S.A. Semuloparin for the prevention of major venous thromboembolism in a patient undergoing major abdominal surgery
EP2446891A1 (en) 2010-10-28 2012-05-02 Aventis Pharma S.A. Semuloparin for use as an antithrombotic treatment in major abdominal surgery with improved safety in terms of clinically relevant bleedings and major bleedings
WO2012072799A1 (en) 2010-12-02 2012-06-07 Aventis Pharma S.A. New methods for the in vitro measurement of the biological activity of an ultra low molecular weight heparin sample
AR085961A1 (es) 2011-04-11 2013-11-06 Sanofi Sa Polisacaridos que poseen dos sitios de union a la antitrombina iii, metodo para prepararlos y composiciones farmaceuticas que los contienen
EP2548561A1 (en) 2011-07-22 2013-01-23 Aventis Pharma S.A. Semuloparin for improving the survival of patients with locally advanced cancer
WO2013044793A1 (zh) * 2011-09-26 2013-04-04 Xu Meiying 一种高纯度肝素苄酯盐及其制法和应用
CN102633908A (zh) * 2012-05-02 2012-08-15 雷晓刚 一种高品质超低分子量肝素的制备方法
ES2445494B1 (es) * 2012-08-02 2015-03-06 Rovi Lab Farmaceut Sa Procedimiento de obtención de heparinas de bajo y muy bajo peso molecular
US9873712B2 (en) * 2014-10-03 2018-01-23 Amphastar Pharmaceuticals, Inc. Method of purifying idraparinux sodium
US20190002596A1 (en) * 2015-12-30 2019-01-03 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Sulfated heparin oligosaccharide and preparation method and application thereof
CZ308106B6 (cs) * 2016-06-27 2020-01-08 Contipro A.S. Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití
CN110917208B (zh) * 2019-12-27 2021-02-12 浙江医院 硫酸化甘露葡萄糖醛酸六糖在防治动脉粥样硬化中的应用
CN117534776A (zh) * 2023-09-26 2024-02-09 南京健友生化制药股份有限公司 一种依诺酯化反应液的除杂方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
FR2482611B1 (fr) * 1980-05-14 1986-03-07 Pharmindustrie Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
FR2504928A1 (fr) * 1981-04-29 1982-11-05 Choay Sa Oligosaccharides a chaines courtes possedant des proprietes biologiques, leur preparation et leurs applications en tant que medicaments
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
FR2584606A1 (fr) * 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
FR2669932B1 (fr) * 1990-12-03 1994-07-01 Sanofi Sa Nouvel heparosane-n,o-sulfate, son procede de preparation et les compositions pharmaceutiques qui le contiennent.
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
FR2807043B1 (fr) * 2000-03-28 2002-11-22 Aventis Pharma Sa Composition pharmaceutique contenant des oligosaccharides, les nouveaux oligosaccharides et leur preparation
FR2811992B1 (fr) * 2000-07-21 2003-07-04 Aventis Pharma Sa Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
FR2845686B1 (fr) * 2002-10-10 2013-08-30 Aventis Pharma Sa Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
UA81925C2 (uk) 2008-02-25
SV2004001626A (es) 2004-03-08
IL167868A (en) 2010-05-31
NO20052170D0 (no) 2005-05-03
CN101812139A (zh) 2010-08-25
PA8584201A1 (es) 2004-08-31
CN1798771A (zh) 2006-07-05
HN2003000312A (es) 2005-10-20
ATE548393T1 (de) 2012-03-15
JP2006517185A (ja) 2006-07-20
JP5389140B2 (ja) 2014-01-15
CA2501546C (fr) 2012-04-03
PT1556414E (pt) 2012-05-21
CN101812190A (zh) 2010-08-25
FR2845686B1 (fr) 2013-08-30
FR2845686A1 (fr) 2004-04-16
NI200300087A (es) 2012-02-02
TNSN05101A1 (fr) 2007-05-14
UY28016A1 (es) 2004-04-30
MXPA05003321A (es) 2005-07-05
CN101810637A (zh) 2010-08-25
TW200418882A (en) 2004-10-01
RU2332424C2 (ru) 2008-08-27
RU2005113987A (ru) 2006-01-27
ZA200502787B (en) 2005-10-18
AU2003300161B2 (en) 2009-08-27
BR0315149A (pt) 2005-08-16
MA27398A1 (fr) 2005-06-01
JP2012051926A (ja) 2012-03-15
AU2003300161A1 (en) 2004-05-04
OA12940A (fr) 2006-10-13
ECSP055722A (es) 2005-07-06
RS20050274A (sr) 2007-06-04
SI1556414T1 (sl) 2012-06-29
WO2004033503A1 (fr) 2004-04-22
ES2383597T3 (es) 2012-06-22
DK1556414T3 (da) 2012-06-25
CN101817940A (zh) 2010-09-01
GT200300181A (es) 2004-03-24
JP5021898B2 (ja) 2012-09-12
CN101812189A (zh) 2010-08-25
MY142376A (en) 2010-11-30
NZ539229A (en) 2008-03-28
CA2501546A1 (fr) 2004-04-22
NO20052170L (no) 2005-07-07
EP1556414A1 (fr) 2005-07-27
TWI332010B (en) 2010-10-21
PE20040507A1 (es) 2004-10-13
EP1556414B1 (fr) 2012-03-07

Similar Documents

Publication Publication Date Title
CY1112808T1 (el) Μειγματα ολιγοσακχαριτων προερχομενων απο την ηπαρινη, η παρασκευη τους και φαρμακευτικες συνθεσεις που τα περιεχουν
Shanmugam et al. Heparinoid-active sulphated polysaccharides from marine algae as potential blood anticoagulant agents
US4791195A (en) Novel oligosaccharides having pharmacological properties by depolymerization of heparin
RU2010122324A (ru) Полисахаридные композиции, не обладающие антикоагулянтными свойствами
SI2794667T1 (en) Low anticoagulant heparins
HRP20180124T1 (hr) Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba
Nishino et al. An anticoagulant fucoidan from the brown seaweed Ecklonia kurome
CA2397964A1 (en) Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
US6197943B1 (en) Glycosaminoglycans having high antithrombotic activity
AR029865A1 (es) Mezclas de polisacaridos sulfatados derivados de la heparina, su preparacion y las composiciones farmaceuticas que las contienen
IT1282994B1 (it) Derivati del polisaccaride k5 aventi elevata attivita' anticoagulante
RU2006106790A (ru) Производные полисахаридов с высокой антитромботической активностью в плазме
Alban et al. Anticoagulant activities of β-1, 3-glucansulfates in dependence on their molecular weight
HRP20230820T1 (hr) Heparan-sulfat, s visokom stopom 3-o-sulfatiranja u glukozaminskim ostacima
JP3218039B2 (ja) 硫酸化多糖類，それらの調製法，医薬組成物および使用
JP2004210715A5 (enExample)
ATE236933T1 (de) Oligosaccharidemischungen mit antithrombotischer wirkung
JPH10218902A5 (enExample)
AR045917A1 (es) Mezclas de oligosacaridos derivados de la heparina, su preparacion y las composiciones farmaceuticas que las contienen
Franz et al. Novel pharmaceutical applications of polysaccharides
JP2005047929A5 (enExample)
TW200704403A (en) Dilution resistant viscoelastic compositions
AR041555A1 (es) Mezclas de polisacaridos derivados de heparina, su preparacion y las composiciones farmaceuticas que las contienen
Sinaÿ Recent advances in the study of the binding site of heparin to antithrombin
RU2005100964A (ru) Эпимеризованные производные полисахарида к5 с высокой степенью сульфатирования